Xenetic Biosciences (NASDAQ:XBIO) reported a 19% increase in royalty revenue for the full year 2025, providing a financial cushion as the company moves closer to human clinical trials for its lead immuno-oncology program.
The Framingham, Massachusetts-based developer of cancer therapies ended the year with a net loss of $2.7 million, an improvement over previous fiscal cycles, while maintaining a cash position of $7.9 million to fund its ongoing research and development efforts.
The company’s financial stability was bolstered by approximately $3 million in royalty income, primarily generated from its long-standing sublicense agreement with Takeda Pharmaceuticals.
This steady revenue stream, combined with an underwritten public offering completed in late 2025, has extended Xenetic’s operational runway as it prioritizes its DNase I platform.
The technology targets neutrophil extracellular traps (NETs)—web-like structures in the body that can shield tumors from the immune system—to improve the efficacy of existing treatments like chemotherapy and CAR-T cell therapies.
On the scientific front, Xenetic transitioned from early proof-of-concept work to more intensive IND-enabling activities.
Management highlighted progress in manufacturing and translational research, specifically aimed at supporting an Investigational New Drug (IND) application with the U.S. Food and Drug Administration.
The year was marked by a strategic emphasis on collaborative research, including investigator-initiated trials evaluating DNase I in combination with standard-of-care treatments for pancreatic ductal adenocarcinoma (PDAC).
Furthermore, the company expanded its partnership with Scripps Research to explore how its DNase platform can enhance CAR-T therapy for large B-cell lymphoma (LBCL).
Preclinical data suggested that degrading NETs may significantly improve T-cell infiltration into tumors, potentially overcoming the immunosuppressive environments that often lead to treatment failure in solid and hematologic cancers.